VIBECOTAMAB

UNII:	JD56EJA59S
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	VIBECOTAMAB
GSRS Full Record:	JD56EJA59S i

2138442-13-2
ANTI-CD123 X ANTI-CD3 BISPECIFIC ANTIBODY XMAB14045
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD3 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB14045 .GAMMA.1-CHAIN), (265->229'),(268->232')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1, ANTI-(HUMAN CD123 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB14045 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB14045 .KAPPA.-CHAIN
IMMUNOGLOBULIN HALF-G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS IL3RA (INTERLEUKIN 3 RECEPTOR SUBUNIT ALPHA, INTERLEUKIN 3 RECEPTOR, ALPHA (LOW AFFINITY), CD123) AND HOMO SAPIENS CD3 EPSILON (CD3E, LEU-4)), MONOCLONAL ANTIBODY, BISPECIFICGAMMA1 HEAVY CHAIN ANTI-IL3RA (1-449) (VH (MUS MUSCULUS IGHV1-26*01(83.7%)-(IGHD)-IGHJ3*01(93.3%)/HOMO SAPIENS IGHV1-46*01 (78.6%)-(IGHD)-IGHJ6*01 (90.9%)) (8.8.13) (1-120)-HOMO SAPIENS IGHG1*03V (CH1 N114>D (211), R120>K (217) (121-218), HINGE 1-15 (219-233), CH2 E1.4>P (236), L1.2>V (237), G1.1>A (238), S29>K (269), Q84.2>E (297) (234-342), CH3 E12 (358), M14 (360), L24>D (370), K26>S (372), N44>D (386), Q97>E (420), N100>D (423) (343-447), CHS (448-449)) (121-449)), (223-220')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI IL3RA (1'-220') (VKAPPA (HOMO SAPIENS IGKV4-1*01 (89.1%)-IGKJ2*01 (91.7%)) (12.3.9) (1'-113')-HOMO SAPIENS IGKC*01 (100%) A45.1 (159), V101 (197) (114'-220'))HEAVY CHAIN SCFV-H-CH2-CH3, ANTI-CD3E (1-485) (VH (HOMO SAPIENS IGHV3-73*01 (87.0%)-(IGHD)-IGHJ6*01 (90.9%)) (8.10.16) (1-125)-20-MER LINKER (126-145)-V-LAMBDA (MUS MUSCULUS IGLV1*01 (80.6%)-IGLJ1*01 (100%)/HOMO SAPIENS IGLV7-46*01 (76.8%)-IGHJ3*02 (100%)) (9.3.9) (146-254)-IGHG1*03 (HINGE 1-15 C5>S (259) (255-269)-CH2 E1.4>P (272), L1.2>V (273), G1.1>A (274), S29>K (305) (270-378),CH3 E12 (394), E13>Q (395), M14 (396), S20>K (402)(379-483), CHS (484-485)) (1-485))DIMER (229-265'':232-268'')-BISDISULFIDE
VIBECOTAMAB [USAN]
Vibecotamab [WHO-DD]
XMAB-14045
XMAB14045
vibecotamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

VIBECOTAMAB

Synonyms and Mappings

Resources